The Adhere Study: evaluating an accessible dietary fibre intervention to improve outcomes in people with breast cancer
About the study
Are you experiencing side effects of your breast cancer treatments? Would you like to try a new approach to improve your symptoms?
The Adhere Study is a new study investigating whether fibre supplements can reduce the side effects of breast cancer treatments. Whether you experience chemobrain, diarrhoea, pain or any other symptoms, we hope that fibre can reduce these to improve your quality of life and make it easier for you to adhere to your treatments.
Study details
You will take a fibre supplement daily for three months and meet with a researcher at commencement and completion of the study, where you will be asked to:
- Donate some blood, faeces (stool) and saliva
- Undergo a brain MRI scan
- Complete a few surveys.
Eligibility requirements
You may be eligible if you:
- Are aged 18 years or older
- Are between 6 and 24 months after your initial diagnosis with breast cancer
- Are receiving systemic treatment for breast cancer (this might be chemotherapy, hormone therapy or targeted therapy and will likely be taken orally)
- Currently experience side effects of your treatment.
You will be ineligible if you:
- Have a gastrointestinal disease (i.e. Crohn’s disease or ulcerative colitis) or are gluten intolerant (i.e. Coeliac’s disease)
- Are currently taking antibiotics.
Recruitment timeline
Start of recruitment: November 2025
End of recruitment: August 2026
Benefits
A gift voucher of $100 will be provided to reimburse you for your time and travel to and from sessions.
